Cue Biopharma, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
CUE$20.14+7.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30,2025 | December 31,2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $11,701 | $22,459 |
| Marketable securities | 6,971 | — |
| Accounts receivable | 387 | 945 |
| Deposits, current portion | 1,747 | 929 |
| Prepaid expenses and other current assets | 3,114 | 805 |
| Foreign withholding tax receivable | 1,899 | — |
| Total current assets | 25,819 | 25,138 |
| Property and equipment, net | 307 | 471 |
| Operating lease right-of-use asset | 4,602 | 4,370 |
| Deposits | 667 | 1,955 |
| Restricted cash | 153 | 152 |
| Other long-term assets | 96 | 105 |
| Total assets | $31,644 | $32,191 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $2,348 | $2,823 |
| Accrued expenses | 1,871 | 2,908 |
| Research and development contract liability, current portion | 7,816 | 85 |
| Operating lease liabilities, current | 2,031 | 3,540 |
| Current portion of long-term debt, net | 1,458 | 4,333 |
| Total current liabilities | 15,524 | 13,689 |
| Operating lease liabilities, non-current | 2,684 | 1,003 |
| Other long-term payable | 190 | — |
| Total liabilities | $18,398 | $14,692 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value; 300,000,000 shares authorized; 77,781,743 and 61,819,101 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 78 | 62 |
| Additional paid in capital | 383,218 | 359,301 |
| Accumulated other comprehensive loss | 1 | — |
| Accumulated deficit | (370,051) | (341,864) |
| Total stockholders’ equity | 13,246 | 17,499 |
| Total liabilities and stockholders’ equity | $31,644 | $32,191 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.